Limited ability of humoral immune responses in control of viremia during infection with SIVsmmD215 strain.

Published

Journal Article

We investigated the impact of rhesus macaque (RM) B-cell depletion before inoculation with the isolate SIVsmmD215. Seven RMs were treated every 3 weeks with 50 mg/kg of an anti-CD20 antibody (rituximab) starting 7 days before inoculation for 2 (n = 4) and 5 (n = 3) months. Four control animals received no antibody. Three animals were completely depleted of CD20(+) B cells, but 4 were only partially depleted of CD20 cells in the LNs and intestine. The decrease in antibody production was consistent with the efficacy of tissue CD20 depletion. Seroconversion and neutralizing antibody production was significantly delayed in animals showing complete tissue CD20 depletion and remained at low titers in all CD20-depleted RMs. Surprisingly, there was no significant difference in acute or chronic viral loads between CD20-depleted and control animal groups. There was a tendency for lower viral set points in CD20-depleted animals. At 6 weeks after inoculation, cellular immune responses were significantly stronger in CD20-depleted animals than in controls. There was no significant difference in survival between CD20-depleted and control animals. Our data suggest that a deficiency of Ab responses did not markedly affect viral replication or disease progression and that they may be compensated by more robust cellular responses.

Full Text

Duke Authors

Cited Authors

  • Gaufin, T; Gautam, R; Kasheta, M; Ribeiro, R; Ribka, E; Barnes, M; Pattison, M; Tatum, C; MacFarland, J; Montefiori, D; Kaur, A; Pandrea, I; Apetrei, C

Published Date

  • April 30, 2009

Published In

Volume / Issue

  • 113 / 18

Start / End Page

  • 4250 - 4261

PubMed ID

  • 19168789

Pubmed Central ID

  • 19168789

Electronic International Standard Serial Number (EISSN)

  • 1528-0020

Digital Object Identifier (DOI)

  • 10.1182/blood-2008-09-177741

Language

  • eng

Conference Location

  • United States